Despite emerging recognition of the subtypes of SCLCs based on high levels of ASCL1 (SCLC-A subtype), NEUROD1 (SCLC-N), POU2F3 (SCLC-P) or YAP1 (SCLC-Y), and other biomarkers including gene amplifications on 4q12 and CCNE1 amplification that could predict the overall survival of patients, the clinical approach to treatment is consistent irrespective (5, 25, 26). This evidence concerns the gene CCNE1 and small cell lung carcinoma.